INTERVIEW
In what ways is Lupin integrating advanced technologies to improve bioprocessing and accelerate the development of recombinant proteins and vaccines?
Lupin is leveraging several advanced technologies to enhance bioprocessing and accelerate the development of recombinant proteins and vaccines. The company utilizes optimized cell line technology platforms to improve the efficiency and yield of recombinant protein production. We employ highthroughput screening methods to expedite the selection and assessment of recombinant proteins. The automation and digitalization are integral to Lupin ' s bioprocessing strategy. Automated systems for cell culture, purification, and quality control enhance consistency and efficiency, while digital tools for data analysis and process monitoring improve decision-making and process optimization. Lupin is exploring modular bioprocessing systems to facilitate flexible and scalable manufacturing. These systems allow for easier transfer of bioprocessing operations across different sites and can be rapidly adapted to meet changing production needs.
What is the transformative role of Artificial Intelligence( AI) and
Machine Learning( ML) in optimizing bioprocessing workflows?
Artificial Intelligence( AI) and Machine Learning( ML) are revolutionizing bioprocessing workflows in several transformative ways. AI and ML can analyze historical data to predict process outcomes, such as product yield, quality, and stability. This predictive capability allows for proactive adjustments to process parameters, minimizing deviations and ensuring optimal performance. ML algorithms can identify optimal process parameters by analyzing vast datasets and experimental results. This reduces the need for extensive trialand-error experiments, accelerating process development and reducing costs.
How do you look at the impact and advantages of Single-Use Technologies( SUTs) in modern biomanufacturing?
Single-Use Technologies( SUTs) minimize the risk of crosscontamination by using disposable components that are pre-sterilized and discarded after use. This is particularly beneficial in multi-product facilities where contamination between batches can be a significant concern. SUTs offer greater flexibility and scalability
28
BioVoiceNews | April 2025